Randomised phase III trials comparing gefitinib and standard platinum-based chemotherapy for patients with EGFR mutations are now being conducted and have the potential to change our daily clinical practice with respect to advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.